A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis

Summary

The study has been designed with three components. Part A is an open label PK study followed by a randomized trial component (Part B) followed by open label Long Term Extension (LTE). The initial PK analysis is first done in adolescent subjects (12 to \<18 years) before initiating the PK study in younger cohort (6 to \<12 years)

Timeline

Start

2020-01-15

Primary completion

2025-04-07

Completion

2031-08-05

Drugs

Indications